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ABSTRACT
Objective: To study the clinical and biochemical profile of patients who develop steroid-induced diabetes (SID) and its predisposing factors.
Methods: Non-diabetic patients aged ≥18 years started on steroids were considered eligible for the study. In every case after detailed examination, 
fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), glycated hemoglobin, fasting insulin were measured prior to starting steroids and 
was repeated in 1st week (day 3/4) after starting steroid according to standard guidelines. FPG and PPG were repeated periodically during follow-up 
of the patients. The utility of Indian diabetic risk score (IDRS) score in predicting the risk for SID was also assessed.
Result: Steroid-induced diabetes was found to be more in females than in males. IDRS is not useful in predicting the risk factors of SID. 97% of patients 
had an elevation of post-prandial sugars with or without fasting hyperglycemia, but only 3% of patients had isolated elevation of fasting blood sugar. 
84% of patients developed SID during the 1st week of therapy. 33% of the cases SID persisted even after 1 month of stopping steroids and on a minimal 
dosage of steroids.
Conclusion: Unlike type 2 diabetes, there were no significant risk factors such as age, family history of diabetes to develop SID and IDRS may not be a 
sensitive tool for predicting risk factors of SID. Monitoring of post-prandial sugars as compared to fasting sugars is essential for the screening of SID. 
Cumulative dose of steroid may not be important to precipitate steroid diabetes.
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INTRODUCTION
Steroids (synthetic steroids) which are potent anti-inflammatory 
agents are normally utilized in the treatment of both acute and chronic 
illness. Their frequent use has resulted in many side effects, which 
includes osteoporosis and diabetes. The diabetogenic effects of steroids 
are a limiting factor to their clinical use.
Despite steroid-induced diabetes (SID) being well-known since 
1940 [1], the impact of its development and risk factors are poorly 
quantified. Previous studies suggest that increasing dose, extent 
of therapy, ethnicity, age, body mass index (BMI), and underlying 
disease may be risk factors for the development of SID [2-5]. However, 
the strength of association of risk factors with the development of 
hyperglycemia remains unclear.
Further, it is not known if SID will remit with discontinuation of steroids. 
The mechanisms of SID are also not clearly elucidated. Hence, the study 
was undertaken to study the clinical and biochemical profile of SID.
METHODS
A case-control study was approved by the Institutional Ethics Committee 
(IEC) of KMC and Hospital, Manipal, Karnataka, India. After obtaining 
informed consent from non-diabetic patients to be started on steroids 
admitted in the Medicine, Nephrology, and Neurology wards of Kasturba 
Hospital, Manipal, Karnataka, India from May 2008 until October 2009 
were recruited into the study and followed up until August 2010.
Inclusion criteria
All individuals without diabetes (by American diabetes association (ADA 
2007 criteria) [6] to be started on steroids were included in the study. 
Participants who developed diabetes (according to the ADA criteria for 
diabetes mellitus, fasting blood sugar >126, and post-prandial blood 
sugar >200) [6] after having starting steroids and were taken as cases 
and those who do not develop diabetes were the controls for the study.
Exclusion criteria
All known diabetics, any patient already on steroids, patients on 
any other drug known to precipitate hyperglycemia and patients in 
pediatric age group.
Study procedure and data analysis
Based on inclusion-exclusion criteria, a total of 100 patients (n=100) 
were recruited in the study. Detailed history including family history 
of diabetes and co-morbidity was recorded. All patients underwent 
basic anthropometry measurement including height, weight, and 
waist circumference. The utility of Indian diabetic risk score (IDRS) 
in predicting the risk for SID was also assessed in the study. Patients 
who developed hyperglycemia after steroid administration were 
considered in SID group and those who do not develop hyperglycemia 
was considered in normoglycemic group.
Fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) 
were repeated periodically during follow-up of the patients. Appropriate 
anti-diabetic medication was started, and therapeutic lifestyle 
modification advised if patients develop diabetes as per their physician’s 
decision. The patients of SID group were followed up for the persistence 
of diabetes on tapering or after stopping steroids during their follow-up.
Statistical analysis
The analysis was performed using SPSS version 11.0. Data were 
presented as mean±standard deviation. The normality assumption 
for continuous variables was evaluated by the Kolmogorov–Smirnov 
test. The categorical variables were represented as percentages or 
proportions. Independent sample t-test was done to compare the mean 
difference between two groups. A p<0.05 was considered significant.
RESULTS
A total of 100 eligible patients were included in and their data were 
analyzed. Out of 100 patients, 59 (59%) were having hyperglycemia 
after starting steroids, and remaining 41 (41%) patients were normal.
Research Article
263
 Rao, et al. 
Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 262-266
The mean age among cases was 41.76±12.80 and that of controls were 
38.76±13.09. This was not statistically significant (p=0.6). The age 
distribution in number and percentages is shown in Fig. 1, showing that 
age did not account for a predictive risk factor for SID.
75% (n=44) of steroid-induced diabetics were females as compared to 
only 25% (n=15) males. This was statistically significant (p=0.008). The 
percentage of males and females among diabetics and non-diabetics is 
shown in Figs. 2 and 3.
Among the controls, 48% (n=20) were females as compared with 51% 
(n=21) males. Among the total of 64 females, 44 (69 %) developed SID, 
whereas only 15 (41%) out of the total of 36 males developed steroid 
diabetes. This was again statistically significant (p=0.008) percentage of 
the total males and females who developed diabetes is shown in Fig. 4.
The mean BMI among cases was 22.26±3.90 and among controls were 
22.12±4.28. However, this was not statistically significant (p=0.5). The 
percentage of patients who developed diabetes under different BMI 
category is shown in Fig. 5.
The family history of diabetes mellitus was not found to be significant 
as only 1 patient among cases, and 3 among the controls had positive 
family history of diabetes mellitus. Similarly, past history of steroid use 
and presence of hypertension were not found to be significant.
Majority of patients, 66.1% (n=39) cases and 56.1% (n=23) controls 
had IDRS score between 30 and 60 27.1% (n=6) of the cases and 36.6% 
(n=15) controls had IDRS score <30. Only 6.8% (n=4) cases and 7.3% 
Fig. 1: Age distribution of the population
Fig. 2: The percentage of males and females among Diabetics and 
non-diabetics
Fig. 3: The percentage of males and females among diabetics and 
non-diabetics
Fig. 4: Percentage of total males and females who developed 
diabetes
(n=3) controls had an IDRS score >60. The IDRS score among the SID 
and normoglycemic is shown in Fig. 6.
Out of the total of 100 patients, 64 patients were given methyl 
prednisolone, 35 patients received prednisolone, and 1 received 
dexamethasone. All the cases received a minimum dosage of 20 mg/
day of prednisolone and maximum of 1 g/day of methylprednisolone. 
The number and percentage of patients who were on various types of 
steroids are shown in Fig. 7.
In 85% (n=50) of the cases, SID was detected in the 1st week after 
initiating steroids.10% (n=6) of the cases developed diabetes after 
1 week but within 1 month after initiating steroids. Only 5% (n=3) 
cases developed diabetes 1 month after starting steroids. The detection 
of SID after the initiation of steroids is shown in Fig. 8.
The detection of SID after the initiation of steroids is shown in Fig. 6. 
52% (n=31) of the cases had isolated elevation of post-prandial 
sugars with normal fasting sugars. 44% (n=26) of the cases had 
both fasting and post-prandial sugars. Only 3% (n=2) had isolated 
elevation of fasting sugars with normal post-prandial sugars. The 
pattern of hyperglycemia among steroid-induced diabetics is shown 
in Fig. 9.
59.32% (n=35) of the cases were managed by diet control and 
lifestyle modification 40.67% (n=24) of the cases were started on oral 
hypoglycemic agents for control of sugars. 6.77% (n=4) of the cases 
required a combination of insulin and oral hypoglycemic agents. 1.69% 
(n=1) required control of sugars with insulin alone. The treatment 
received by the patients is shown in Fig. 10.
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The patients were followed up for a period of 1-year after starting 
steroids to look for the persistence of diabetes on tapering or after 
stopping steroids. On tapering doses and after stopping steroids 
>1 month, it was seen that 66.10% (n=39) cases were in remission. 
28.81% (n=17) patients persisted to have SID. The follow-up of 
patients 1 month after having stopped taking steroids is shown in Fig. 
11.
Among them, 23.72% (n=14) cases were on a minimal dosage of steroids 
(prednisolone 5 mg, methyl prednisolone 4 mg) while 5% (n=3) cases 
were totally off steroids. 5% (n=3) cases were lost for follow-up.
The difference in pre- and post-fasting insulin levels before and 
after starting steroids were done among 29 cases and had a mean of 
11.72±16.96. Among the 24 controls, the mean was 15.33±16.68. 
This was not found to be statistically significant. However, the higher 
insulin reserve among controls than in cases may have prevented them 
from developing SID probably due to better insulin reserve. These 
observations merit further studies.
DISCUSSION
The study included 100 patients fulfilling inclusion, exclusion criteria, and 
found 59 (59%) were having hyperglycemia after starting steroids The 
incidence of SID was not constant across studies; it ranges from 1.5% to 
47%. The variability of this occurrence is due to the differences in patient 
population, different treatment protocols and definition of diabetes [3].
In our study, the mean age of persons who developed steroid diabetes 
was 41 years; the maximum number of patients in our study were in 
their fourth and fifth decades. We found that 60% (n=40) of the cases 
were above the age of 40 years, whereas only 40% (n=16) of the 
controls were in the age group of above 40 years. This was correlating 
with other studies where the incidence of SID increased with age [7-9]. 
However, this was not found to be statistically significant (p=0.6). 
Glucose intolerance may be due to decreased sensitivity of pancreatic 
cells to glucagon-like peptide 1 and to alterations of hepatic glucose 
production [10]. These mechanisms may explain the development of 
SID in the elderly. However, in this study, the risk of developing SID was 
independent of age.
The study did not show any correlation between family history and the 
development of steroid diabetes as only one subject among cases and 
3 among the controls had positive family history of diabetes mellitus. 
However, these results may be limited by the fact that the number of 
patients with family history of diabetes was low. Similarly, past history 
of steroid use, family history of obesity, and hypertension were not 
found to be significant.
Similarly, there was no correlation between BMI and development of 
SID. The mean BMI among cases was 22.26±3.90 and among controls 
was 22.12±4.28. These findings were consistent with the study by 
Takuya et al. and Raúl Ariza-Andraca et al. [9,11]. However, other 
studies by Arner et al. did report a significant correlation with these 
factors [7].
The risk factors for SID have not been clearly defined. The traditional 
risk factors for type 2 DM such as age, abdominal obesity, family history, 
and physical activity have been incorporated in the IDRS [12]. The risk 
score was derived from the Chennai Urban Rural Epidemiology Study 
by Mohan et al. IDRS depends on the four simple variables, namely age, 
Fig. 5: Percentage of patients who developed diabetes under 
different categories of body mass index
Fig. 6: Indian diabetic risk score among steroid-induced diabetes 
group and normoglycemia group
Fig. 7: Number and percentage of patients who were on various 
steroids
Fig. 8: The time of detection of steroid-induced diabetes after 
initiation of steroids
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controls and found no significant difference in the cumulative scores 
as well as among the individual risk factors. Consequently, the IDRS 
score was not useful in predicting the risk of developing SID. Further 
another study done recently by Vikram et al. also showed no correlation 
between IDRS and SID [13].
In the present study, an attempt was made to quantify the dose of steroid 
that induced diabetes in susceptible patients. All patients in the study 
were taking a minimum dose of 30 mg/day or greater of prednisolone 
while the dose for methylprednisolone was 1 g/day or greater. The 
literature also shows that hyperglycemia develops in patients who 
were on a dose of 30 mg/day of prednisolone or its equivalent [14]. 
Greenstone et al. have shown that patients taking alternate day steroid 
have greater impairment of glucose tolerance on the corticosteroid day 
than on the alternate day [15].
Further, whether the dose or duration of exposure to steroid causes SID 
is still controversial across many studies [2,13]. In the present study, 
85% of patients developed steroid diabetes within 7 days of starting 
steroids, whereas a minority had hyperglycemia detected after a month 
of therapy. This could indirectly imply that cumulative dose may not 
be a risk factor for steroid diabetes; however, these findings still merit 
further studies. The fact remains that we must aggressively look for 
steroid diabetes in the first few weeks after having initiated steroids.
However, there was no statistically significant correlation between the 
development of steroid diabetes and the cumulative dose of steroid 
required studies on the cumulative dose show conflicting results across 
studies [11]. According to Vikram et al., 100% of patients developed 
SID in the 1st week of steroid exposure [13]. These results indicate that 
cumulative dose may not be a risk factor [6]. However, other studies 
by Kim et al. and Van Raalte et al. [2,4] commented that cumulative 
dose, and long duration of steroid therapy and susceptibility of the 
population exposed may be the important risk factors.
The present study found that 97% of patients had an elevation of 
post-prandial sugars with or without fasting hyperglycemia, but only 
3% of patients had isolated elevation of fasting blood sugars. It was 
previously reported that when only fasting glucose concentration 
was monitored to detect steroid diabetes, the prevalence of steroid 
diabetes was 46% in renal transplant recipients who received high 
dose steroid therapy [7]. Failure to monitor PPG may underestimate 
the incidence of steroid diabetes cases. Iwamoto et al. have reported 
a close relationship between post-prandial hyperglycemia and SID 
in patients with neurologic diseases [9]. Their study showed that the 
mean plasma glucose concentration after lunch was highest among 
the concentrations at post-prandial points. Although the mean time of 
maximum plasma concentration and the half-life of prednisolone are 
1.3 and 2.2 h after oral administration, respectively [16], the drug might 
continue to be active during the daytime. Several studies have revealed 
that post-prandial hyperglycemia including impaired glucose tolerance 
is a risk factor for mortality [17-19].
In most of the patients, the level of hyperglycemia was around 250 mg/
dL. This warranted pharmacotherapy in about 50% of the patients, 
most of them being on oral hypoglycemic agents. The rest were being 
managed with lifestyle modifications; however, a previous study had 
reported that steroid diabetes is similar to type 2 diabetes mellitus, 
except that it often requires insulin therapy [7]. The literature states that 
if the FPG is near normal range, oral diabetic agents (e.g. sulfonylureas, 
metformin) maybe sufficient to reduce hyperglycemia. However, if the 
FPG is >200 mg/dl, oral agents are usually not efficacious, and insulin 
therapy is required. Trence et al. have reported that steroid diabetes is 
treated primarily with prandial insulin, either regular or rapid insulins 
(lispro or aspart), intermediate insulin being indicated less frequently 
for fasting hyperglycemia [20].
In a preliminary follow-up of patients who had stopped steroids for more 
than 1 month or were on the tapering dosage of steroids, it was found 
Fig. 9: Pattern of hyperglycemia among steroid induced diabetes
Fig. 10: Treatment received by patients
Fig. 11: Follow-up of patients 1 month after stopping steroids
family history of diabetes, waist circumference, and physical activity 
are used to identify undiagnosed diabetes in the community. Briefly, 
the definite data on these risk factors was acquired by four questions. 
These are given scores derived from the logistic regression. Patients 
with score <30 were divided as low risk, those between 30 and 50 as 
medium risk and those with ≥60 as high risk for diabetes. IDRS value 
≥60 which has sensitivity of 72.5% and specificity 60.1% in detecting 
undiagnosed diabetes in the general population or its components [12]. 
Thus, if IDRS can predict the risk of developing SID, further studies can 
be done to screen the population for undiagnosed diabetes. Follow-up 
of these individuals who develop type 2 diabetes or have persistence 
of SID will help us in assessing the utility of IDRS in predicting SID and 
future risk of type 2 diabetes.
In our study, we analyzed all patients for the presence of these risk 
factors. We compared the prevalence of these risk factors in cases and 
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that about 33% persisted to have sugars in the diabetes range. Thus, 
steroids may be unmasking diabetes in a significant number of patients 
which will have to be confirmed by future studies. There are conflicting 
results on the persistence of hyperglycemia on stopping steroids. Some 
studies reported that impaired glucose tolerance-induced by steroids 
may continue for about 24 h when the steroid is administered once a 
day [21]. Vikram et al. have reported that sugars come to the normal 
range 1 week after stopping therapy while some have also reported that 
the effect of glucocorticoids on hyperglycemia usually remit within 48 h 
of discontinuation of oral administration [13,22].
Diabetic ketoacidosis is a rare complication of steroid-induced 
diabetes [23]. In our study, no patient developed diabetic ketoacidosis 
or other acute complications of hyperglycemia.
CONCLUSION
To conclude, the study did not reveal any significant risk factors which 
could predict the development of SID. The IDRS, which was very useful 
in predicting the risk of type 2 diabetes, was not found helpful in 
determining the risk of developing SID.
Steroid-induced diabetes is essentially an exaggeration of post-prandial 
hyperglycemia. Hence, monitoring of post-prandial sugars as compared 
to fasting sugars is essential, especially in the 1st week after initiating 
steroids. The majority of individuals who develop SID can be managed 
with diet and lifestyle modification without any pharmacological 
therapy.
In almost 30% of the cases, SID persisted even after 1 month of 
stopping steroids when on a minimal dosage of steroids. Thus, there is 
a significant reason to believe that steroids may aid in the unmasking of 
diabetes in a significant number of patients. Further, studies are to be 
undertaken to validate this hypothesis.
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